Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American:IGC) announced the expansion of its Phase 2 CALMA clinical trial for IGC-AD1, a novel treatment for agitation in Alzheimer's dementia, to Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada.
The CALMA trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of IGC-AD1 in managing agitation in Alzheimer's patients. This expansion strengthens the trial's clinical infrastructure across North America and aims to increase access for patients and caregivers while supporting timely enrollment towards trial completion.
IGC Pharma (NYSE American:IGC) has received a Notice of Allowance from the USPTO for patent application US 17/613,909 (IGC510), covering a novel treatment method using THC and/or CBD for stammering, stuttering, and Tourette's syndrome. The therapeutic approach combines microdoses of THC with atypical antipsychotics to target the endocannabinoid system.
The treatment aims to serve an estimated 75 million people globally affected by these conditions. The patent adds to IGC's portfolio, which includes treatments for Alzheimer's, pain, and eating disorders. The company plans to develop clinical formulations similar to their flagship medication IGC-AD1, currently in Phase 2 CALMA clinical trials.
IGC Pharma (NYSE American:IGC) announced that Ascendiant Capital Markets has released a new coverage report on the company. The report raises the price target to $4.50 and suggests that upcoming clinical data and progress in 2025 could serve as strong catalysts for the stock.
The company explicitly stated that analyst views represent their independent opinions and that IGC Pharma is not responsible for the content, accuracy, or timelines provided in such reports.
IGC Pharma (NYSE American:IGC) has expanded its Phase 2 clinical trial for IGC-AD1, a drug candidate targeting agitation in Alzheimer's disease patients, by adding a new site at the Lynn Health Science Institute (LHSI) in Oklahoma City.
The CALMA trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Carl Griffin at the new site. The trial aims to evaluate IGC-AD1's safety and efficacy in addressing one of Alzheimer's most challenging symptoms - agitation, which often leads to earlier institutionalization and increased caregiver stress.
IGC Pharma (NYSE American:IGC) reported Q1 fiscal 2026 financial results, highlighting progress in its Phase 2 CALMA trial for Alzheimer's disease treatment. Revenue increased 21% to $328,000 compared to Q1 FY2025. The company reduced its net loss to $1.6 million ($0.02 per share) from $2.3 million year-over-year.
Notable achievements include expansion of trial sites across North America for IGC-AD1, a cannabinoid-based treatment for Alzheimer's agitation, advancement of MINT-AD AI platform for early Alzheimer's detection, and extension of an undrawn $12 million credit facility with O-Bank. The company successfully reduced SG&A expenses by 28% to $1.2 million and raised $3.5 million through private placements and ATM offering.
IGC Pharma (NYSE:IGC) announced promising preclinical results for two Alzheimer's disease treatments. Their lead candidate IGC-M3, a novel small molecule, demonstrated significant activity against multiple Alzheimer's pathology drivers, including over 90% prevention of beta-amyloid fibril formation and superior antioxidant performance compared to vitamin C.
The company is pursuing a dual-strategy approach with IGC-AD1, a cannabinoid-based therapy currently in Phase 2 clinical trials for Alzheimer's-related agitation, and IGC-M3, targeting multiple disease mechanisms in preclinical development. IGC-AD1 utilizes THC to address agitation affecting up to 76% of Alzheimer's patients, while IGC-M3 shows promise in disease modification through multiple pathways including amyloid reduction, metal ion regulation, and inflammation control.
IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its investigational molecule IGC-M3 in the treatment of Alzheimer's disease. The in vitro studies demonstrate that IGC-M3 targets multiple biological mechanisms central to Alzheimer's pathology through four key actions:
The compound has shown ability to inhibit amyloid aggregation, promote disassembly of amyloid aggregates, neutralize reactive oxygen species, and reduce pro-inflammatory signaling in cellular models. In SH-SY5Y human neuronal cells, IGC-M3 demonstrated neuroprotective effects, while in BV2 microglial cells, it reduced Aβ42-induced activation and decreased pro-inflammatory markers.
The company plans to advance IGC-M3 to in vivo studies to evaluate its potential efficacy and safety in animal models, aiming to develop a disease-modifying treatment for Alzheimer's.
IGC Pharma (NYSE American: IGC) announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The presentations will showcase the company's AI-driven innovations in Alzheimer's disease research.
The posters will highlight: 1) MINT-AD, an AI foundation model trained on 100+ global datasets for Alzheimer's risk assessment, 2) Research on using large language models to predict cognitive scores without brain scans or blood biomarkers, and 3) An AI-powered drug discovery pipeline focusing on GLP-1 and CB1 targets for Alzheimer's treatment.
IGC Pharma (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, announced that its Principal Scientist, Dr. Jagadeesh Rao, has received the Best Researcher Award at the 11th Annual World Neuroscientist Awards. The recognition comes from an international panel of experts, highlighting his 15+ years of scientific leadership in neuroscience research.
Dr. Rao's work has been crucial in advancing IGC-AD1, the company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients. His selection came from a competitive pool of over 360 nominations across 125 countries.
IGC Pharma (NYSE American:IGC) has unveiled MINT-AD, an AI-powered diagnostic platform designed to identify individuals at high risk of Alzheimer's disease before symptoms manifest. The Multimodal Interpretable Transformer for Alzheimer's platform integrates diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics to generate risk profiles and cognitive decline forecasts.
The company plans to launch a beta version in Fiscal 2026 for pilot evaluation with academic and clinical partners. MINT-AD aims to address the global diagnostic gap, where over 400 million people may have Alzheimer's-related pathology before clinical symptoms appear. The platform is designed to extend cognitive diagnostics beyond specialized facilities to general practices and underserved populations.